A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 Against COVID-19 in Adults

NCT05011526 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1030

Enrollment

INDUSTRY

Sponsor class

Conditions

Covid19 Vaccine

Interventions

BIOLOGICAL: MVC-COV1901
BIOLOGICAL: AZD1222

Sponsor

Medigen Vaccine Biologics Corp.